For a longer and better life with Cystic Fibrosis
Hilde de Keyser
0032 - (0)2 61 32 716
For the 9th time young scientists in CF met senior scientists in CF during the European Young Investigator Meeting.
Out of 64 students that submitted an abstract, 36 students participated in the EYIM 2015. Together with 10 senior scientists/clinicians they discussed CF relevant topics within the sessions, round tables and network events.
Please find the report of this event here:
The results of a phase III trial for a new treatment for people with cystic fibrosis aged 12 and over with two copies of the F508del mutation have been published.
The results, released by Vertex Pharmaceuticals Ltd, demonstrate that this combination of ivacaftor and lumacaftor could offer this group of people with cystic fibrosis an additional treatment option and a first therapy that targets the basic genetic defect.
Stem cells with Cystic Fibrosis have been repaired in the laboratory.
Researchers of the Dutch Hubrecht Institute and the University Medical Centre Utrecht
have been able to repair stem cells with Cystic Fibrosis. They have cut out the CFcausing
defect from intestinal stem cells and replaced it by a “healthy piece”. ‘This is
a major step in the road to cure Cystic Fibrosis. Very hopeful. Patients will not benefit
immediately, but technology is moving forward’, says Jacquelien Noordhoek, CEO of
the Dutch Cystic Fibrosis Foundation NCFS.